Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | BLVRB | P30043 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3468631 | 0.91 | MAPT (0.50) | NPC1RAB9AMAPTTP53POLB | |
| SCHEMBL3455957 | 0.89 | NPC1 (0.50) | NPC1RAB9AMAOABLVRBHDAC6 | |
| SCHEMBL3456402 | 0.89 | NPC1 (0.48) | NPC1RAB9AMAOABLVRBHDAC6 | |
| SCHEMBL3766906 | 0.83 | MAPT (0.53) | NPC1RAB9AMAPTS1PR1TP53 | |
| SCHEMBL3465830 | 0.83 | MAOA (0.46) | NPC1RAB9AMAOABLVRBHDAC6 | |
| SCHEMBL3755918 | 0.82 | MAPT (0.46) | NPC1RAB9AMAOABLVRBHDAC6 | |
| SCHEMBL3761171 | 0.80 | MAPT (0.54) | NPC1RAB9AMAOABLVRBHDAC6 | |
| SCHEMBL3759010 | 0.80 | NPC1 (0.55) | NPC1RAB9AMAPTS1PR1TP53 | |
| SCHEMBL20406019 | 0.79 | MAPT (0.44) | NPC1RAB9AMAOABLVRBHDAC6 | |
| SCHEMBL20405702 | 0.79 | DHODH (0.44) | NPC1RAB9ADHODHALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250165-B1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2018-07-25 | — | — | EP | disclosed |
| EP-2250165-B1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| WO-2009080663-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | OXA1L, RO60, PDCD11 | NPC1 4730/4885RAB9A 2114/4885MAOA 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.